|
|
Iranian Heart Journal، جلد ۲۶، شماره ۲، صفحات ۶۶-۷۶
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Empagliflozin Effects on Supraventricular Arrhythmias in Heart Failure Patients With Implantable Cardioverter-Defibrillator |
|
| چکیده انگلیسی مقاله |
Background: Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), is a primary pharmacological therapy for chronic heart failure (CHF). Notably, it has demonstrated anti-arrhythmic properties in some experimental and human studies. This clinical trial aimed to evaluate the effect of empagliflozin on supraventricular arrhythmias in patients with CHF and an implantable cardioverter-defibrillator (ICD).
Methods: In a before-and-after clinical trial conducted in Tehran, Iran, 62 patients were administered empagliflozin 10 mg/d for 12 weeks. The frequency and proportion of supraventricular arrhythmias, including atrial fibrillation (AF), atrial flutter (AFL), and inappropriate ICD therapies during the 12-week treatment period were compared with the 12 weeks before enrollment. Hospitalizations due to CHF, blood glucose levels, lipid profiles, and vital signs were also assessed as secondary outcomes.
Results: Empagliflozin significantly reduced the frequency of supraventricular tachycardia and AF/AFL per hour (P = 0.028 and P = 0.038, respectively). However, the frequency of inappropriate therapies and the proportion of patients with supraventricular arrhythmias or inappropriate ICD therapies did not change significantly. Empagliflozin also reduced hospitalizations due to CHF (P = 0.008). Furthermore, fasting blood sugar, HbA1c, triglycerides, systolic blood pressure, diastolic blood pressure, heart rate, and high-density lipoprotein levels improved after 12 weeks (P < 0.001, P < 0.003, P < 0.013, P < 0.001, P < 0.032, P < 0.009, and P < 0.008, respectively).
Conclusions: Empagliflozin exhibits anti-arrhythmic properties for AF/AFL in individuals with CHF and an ICD. These anti-arrhythmic effects may be attributed to its positive impact on hyperglycemia, hypertension, dyslipidemia, and hospitalizations due to CHF. (Iranian Heart Journal 2025; 26(2): 66-76) |
|
| کلیدواژه‌های انگلیسی مقاله |
arrhythmia,Atrial Fibrillation,Empagliflozin,Implantable Cardioverter-defibrillator,SGLT2 inhibitor |
|
| نویسندگان مقاله |
Majid Shohrati |
Department of Clinical Pharmacy, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Morteza Khodaparast |
Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Mahdi Bagheri |
Department of Clinical Pharmacy, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Mohammad Tayyebi |
Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
|
|
| نشانی اینترنتی |
https://journal.iha.org.ir/article_217916_1215f7057e4ca74670d41490c75fb7bc.pdf |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
|
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|